Can I Take Magnesium with Repatha (Evolocumab)?

Why There Is No Direct Interaction

Repatha (evolocumab) and magnesium operate through entirely separate biological systems. No pharmacokinetic overlap exists, and the pharmacodynamic profiles do not conflict.

How Evolocumab Is Metabolized

Evolocumab is a fully human IgG2 monoclonal antibody that binds proprotein convertase subtilisin/kexin type 9 (PCSK9). Like all therapeutic monoclonal antibodies, it is cleared from the body through receptor-mediated endocytosis and proteolytic catabolism, not through cytochrome P450 enzymes or renal excretion [2]. This means oral substances, whether drugs or supplements, cannot compete for the same metabolic enzymes. The FDA-approved prescribing information for Repatha lists no drug-drug interactions and no supplement contraindications [3].

How Magnesium Is Absorbed and Cleared

Dietary and supplemental magnesium is absorbed primarily in the small intestine via transient receptor potential melastatin (TRPM6 and TRPM7) channels and paracellular diffusion [4]. The kidneys regulate magnesium homeostasis by adjusting tubular reabsorption. None of these pathways intersect with IgG2 antibody catabolism. Magnesium does not bind to PCSK9, does not alter LDL receptor recycling, and does not change the subcutaneous absorption kinetics of injected biologics.

A 2020 review in Nutrients examining magnesium interactions with cardiovascular drugs found no reported adverse events or efficacy changes when magnesium was combined with monoclonal antibody therapies [5].

Why Magnesium Still Matters for Repatha Patients

Although there is no interaction between these two agents, patients prescribed evolocumab often have clinical profiles that make magnesium status worth monitoring. The reason is not Repatha itself. It is the other medications these patients are typically taking.

The Statin-Magnesium Connection

Most Repatha patients are already on maximally tolerated statin therapy. In the FOURIER trial (N=27,564), 69.3% of participants were on high-intensity statins [1]. Statins have been associated with skeletal muscle complaints in 5% to 29% of users, depending on the definition and study design [6]. A 2019 cross-sectional analysis published in Atherosclerosis (N=1,236) found that patients reporting statin-associated muscle symptoms had significantly lower serum magnesium levels (0.78 mmol/L vs. 0.83 mmol/L, P=0.003) compared to asymptomatic statin users [7]. Low intracellular magnesium may impair mitochondrial ATP production in myocytes, potentially compounding statin effects on the mevalonate pathway.

PPI and Diuretic Depletion

Patients with established atherosclerotic cardiovascular disease (ASCVD) frequently take proton pump inhibitors for gastroprotection or thiazide/loop diuretics for hypertension or heart failure. The FDA issued a safety communication in 2011 warning that PPIs used for longer than one year can cause clinically significant hypomagnesemia [8]. Thiazide diuretics increase renal magnesium wasting through reduced distal tubule reabsorption. A 2021 meta-analysis in The American Journal of Medicine (14 studies, N=115,455) found PPI users had a 43% increased risk of hypomagnesemia (OR 1.43, 95% CI 1.08 to 1.88) [9].

For Repatha patients already managing multiple cardiovascular risk factors, these medication-driven depletions create a practical reason to assess magnesium status even though Repatha itself does not affect it.

Checking Your Magnesium Level

A serum magnesium test is inexpensive and widely available, but it reflects only about 1% of total body magnesium. Normal serum range is 1.7 to 2.2 mg/dL (0.70 to 0.90 mmol/L) [10].

When to Test

The Endocrine Society and the American Association of Clinical Endocrinologists (AACE) recommend checking serum magnesium when patients present with muscle cramps, arrhythmias, or fatigue that is not explained by other causes [11]. For Repatha patients specifically, consider testing at baseline if any of the following apply:

• Current PPI use exceeding three months
• Thiazide or loop diuretic use
• Type 2 diabetes (renal magnesium wasting is common)
• Statin-associated muscle symptoms
• Chronic kidney disease stages 3 to 5

Interpreting Results

A level below 1.7 mg/dL warrants repletion. Levels between 1.7 and 1.8 mg/dL may still represent subclinical deficiency, particularly in patients with symptoms [10]. Red blood cell (RBC) magnesium is sometimes used as a surrogate for intracellular stores, though its clinical utility remains debated. A 2021 consensus statement in Open Heart noted that serum magnesium misses up to 50% of true deficiency cases and recommended pairing it with 24-hour urine magnesium when clinical suspicion is high [12].

Choosing a Magnesium Supplement

Not all magnesium formulations deliver the same amount of elemental magnesium or absorb equally well. For cardiovascular patients on Repatha, the choice of form matters more than the brand.

Bioavailability Differences

Magnesium citrate and magnesium glycinate demonstrate 25% to 30% higher fractional absorption compared to magnesium oxide in randomized crossover studies [13]. Magnesium oxide, despite containing more elemental magnesium per tablet (60% by weight), has bioavailability as low as 4% in some preparations [13]. Magnesium taurate has drawn interest in cardiovascular populations because taurine itself may have antiarrhythmic properties, though evidence remains preliminary [14].

Dosing Guidelines

The National Institutes of Health Office of Dietary Supplements sets the tolerable upper intake level (UL) for supplemental magnesium at 350 mg/day of elemental magnesium for adults [10]. This UL applies to supplements only, not dietary magnesium from food. For repletion of documented deficiency, clinicians may prescribe higher doses under monitoring.

A practical framework for Repatha patients:

• No deficiency, general supplementation: 200 to 350 mg elemental magnesium daily (citrate or glycinate preferred)
• Subclinical deficiency (serum 1.7 to 1.8 mg/dL with symptoms): 400 mg daily for 8 to 12 weeks, then recheck
• Overt hypomagnesemia (serum <1.7 mg/dL): Physician-directed repletion, often 400 to 800 mg daily in divided doses, with periodic serum monitoring

Gastrointestinal tolerance is the most common limiting factor. Magnesium citrate and oxide cause loose stools more frequently than glycinate or taurate at equivalent elemental doses.

Magnesium and Cardiovascular Outcomes

Beyond the absence of interaction with Repatha, magnesium has its own evidence base in cardiovascular risk reduction. This is relevant because Repatha patients are, by definition, a high-cardiovascular-risk population.

Epidemiologic Data

A 2013 meta-analysis in Atherosclerosis (16 prospective cohort studies, N=313,041) found that a 0.2 mmol/L increase in circulating magnesium was associated with a 30% lower risk of cardiovascular disease (RR 0.70, 95% CI 0.56 to 0.88) and a 22% lower risk of ischemic heart disease (RR 0.78, 95% CI 0.67 to 0.92) [15]. A dose-response analysis within the same review showed that each 200 mg/day increment in dietary magnesium intake correlated with a 22% reduction in heart failure risk.

Effect on Insulin Sensitivity

ASCVD and insulin resistance frequently coexist. A 2016 randomized, double-blind trial published in Diabetes & Metabolism (N=116) found that 382 mg/day of magnesium chloride for 16 weeks improved HOMA-IR by 32.4% and reduced fasting glucose by 10.5% in adults with prediabetes and hypomagnesemia compared to placebo [16]. For Repatha patients with concurrent metabolic syndrome, maintaining adequate magnesium may support glycemic control independently of lipid management.

Blood Pressure Effects

A 2017 meta-analysis of 34 randomized controlled trials (N=2,028) in Hypertension showed that magnesium supplementation at a median dose of 368 mg/day for a median duration of 3 months reduced systolic blood pressure by 2.00 mmHg (95% CI 0.43 to 3.58) and diastolic blood pressure by 1.78 mmHg (95% CI 0.73 to 2.82) [17]. The effect was stronger in trials where participants were magnesium-deficient at baseline. For ASCVD patients on antihypertensives, this represents a modest but additive benefit.

Timing and Practical Considerations

Because no interaction exists, there is no pharmacologic reason to separate Repatha injections and magnesium supplement doses.

Injection Day Logistics

Repatha is administered as a 140 mg subcutaneous injection every two weeks or 420 mg once monthly [3]. Patients sometimes ask whether they should avoid supplements on injection day. There is no basis for this concern. The subcutaneous injection enters the bloodstream through lymphatic drainage over several days, while oral magnesium is absorbed in the gut. These are parallel, non-competing processes.

If You Are Already Taking Both

Patients currently combining Repatha and magnesium should continue without changes. No case reports, post-marketing surveillance signals, or mechanistic evidence suggest any reason to modify either agent. The FDA Adverse Event Reporting System (FAERS) database does not flag magnesium as a co-reported supplement in evolocumab adverse event cases [3].

What to Tell Your Prescriber

Inform your prescribing clinician about all supplements, including magnesium. This is not because of an interaction risk with Repatha but because magnesium can interact with other drugs in a cardiovascular regimen. Magnesium can reduce the absorption of bisphosphonates, tetracycline antibiotics, and certain fluoroquinolones through chelation [10]. If you take any of these, a two-hour separation window is appropriate.

When Magnesium Could Be Harmful

Magnesium supplementation is not appropriate for all patients. Renal impairment changes the risk profile significantly.

Renal Impairment Caution

Patients with an estimated glomerular filtration rate (eGFR) below 30 mL/min/1.73 m² are at risk for hypermagnesemia because the kidneys cannot adequately excrete excess magnesium [10]. Symptoms of hypermagnesemia include hypotension, bradycardia, respiratory depression, and in severe cases, cardiac arrest. The FOURIER trial excluded patients with eGFR <20 mL/min/1.73 m², but did include patients with moderate CKD [1]. If your kidney function is reduced, magnesium supplementation requires physician oversight and periodic serum monitoring.

Drug-Specific Separation Needs

While Repatha requires no separation, other drugs in a typical ASCVD regimen do:

• Levothyroxine: Separate magnesium by at least four hours
• Bisphosphonates (alendronate, risedronate): Separate by at least two hours
• Certain antibiotics (tetracyclines, fluoroquinolones): Separate by at least two hours before or four to six hours after magnesium

These separation windows protect the absorption of the co-administered drug, not magnesium itself.

What the Evidence Does Not Yet Show

No randomized trial has specifically tested whether magnesium supplementation improves clinical outcomes in patients taking PCSK9 inhibitors. The cardiovascular benefit data for magnesium come from general population studies and observational cohorts [15]. Whether magnesium provides additive benefit on top of aggressive LDL-C lowering with evolocumab (which reduced LDL-C to a median of 30 mg/dL in FOURIER [1]) remains an open question. Ongoing research into the role of magnesium in endothelial function and arterial calcification may eventually clarify this, but current prescribing decisions should be guided by magnesium status and deficiency risk rather than any presumed combination with Repatha.

Patients with serum magnesium below 1.8 mg/dL and concurrent statin-associated muscle symptoms should discuss a 12-week repletion trial of 400 mg elemental magnesium (as citrate or glycinate) with their prescriber, followed by a repeat serum level.